PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molvisLink to Publisher's site
 
Mol Vis. 2010; 16: 2760–2764.
Published online 2010 December 15.
PMCID: PMC3012648

Variation in OPA1 does not explain the incomplete penetrance of Leber hereditary optic neuropathy

Abstract

Purpose

Leber hereditary optic neuropathy (LHON) is a common cause of inherited blindness, primarily due to one of three mitochondrial DNA (mtDNA) mutations. These mtDNA pathogenic mutations have variable clinical penetrance. Recent linkage evidence raised the possibility that the nuclear gene optic atrophy 1 (OPA1) determines whether mtDNA mutation carriers develop blindness. To validate these findings we studied OPA1 in three independent LHON cohorts: sequencing the gene in discordant male sib pairs, carrying out a family-based association study of common functional genetic variants, and carrying out a population-based association study of the same genetic variants.

Methods

We tested 3 hypothesis in three separate study groups. Study group 1: Direct sequencing of OPA1 coding regions was performed using sequencing methodologies (Applied Biosystems, Foster City, CA). Chromatograms were compared with the GenBank reference sequence NM_015560.1. Splice-site prediction was performed using GeneSplicer. Study group 2: Genotyping for rs166850 and rs10451941 was performed by restriction fragment length polymorphism (RFLP) analysis with specific primers for both genotypes, using The restriction enzymes RsaI and FspBI to discriminate genotypes. Study group 3: Genotyping for rs166850 and rs10451941 was performed by primer extension of allele-specific extensions products by matrix-associated laser desorption/ionisation time-of-flight (MALDI-TOF, Seqeunom, San Diego, CA) mass spectrometry. Allele and genotype frequencies were compared using Pearson’s chi-square test. Multiple logistic regression was performed to look for interactions between the variables. All analyses were performed using SPSS software version 17.0 (SPSS Inc.).

Results

In all three groups we were unable to find an association between OPA1 genetic variation and visual failure in LHON mtDNA mutation carriers.

Conclusions

Our findings suggest that genetic variation in OPA1 is unlikely to make a major contribution to the risk of blindness in LHON mutation carriers.

Introduction

Leber hereditary optic neuropathy (LHON, OMIM 535000) is a common cause of inherited blindness that typically presents with bilateral, painless, subacute visual failure in young adult males [1]. Affected individuals develop focal degeneration of the optic nerve and present clinically with impaired color vision (dyschromatopsia), a dense visual field defect (central or cecocentral scotoma), and abnormal visual electrophysiology due to primary retinal ganglion cell loss [1]. The diagnosis is usually confirmed by molecular genetic analysis for one of three common mitochondrial DNA (mtDNA) mutations, which all affect genes coding for complex I subunits of the respiratory chain: m.3460G>A, m.11778G>A, and m14484T>C. However, not all patients harboring a pathogenic LHON mtDNA mutation develop visual failure [2]. Segregation analysis of LHON pedigrees implicates a two-locus model, with the mtDNA mutation as one locus, together with a modulating chromosomal locus [3]. Attempts to identify a nuclear modifying gene by both genetic mapping and functional genomics have been inconclusive [4-6]. Recently, a region of chromosome 3 was identified as important in determining the risk of visual loss in LHON [7]. Although this work led to a report associating the presenilin associated, rhomboid-like (PARL) gene with the LHON phenotype, the same linkage region harbors optic atrophy 1 (OPA1), a gene critical to mitochondrial function. This raises the possibility that the PARL association was mediated through linkage disequilibrium with the OPA1 gene.

OPA1 is a nuclear gene coding for a mitochondrial protein critical for mtDNA maintenance, effective oxidative phosphorylation, and maintenance of the mitochondrial network [8-10]. Mutations in OPA1 are a principle cause of autosomal dominant optic atrophy (DOA) [11-13]. Like LHON, DOA has a markedly variable clinical phenotype, and both disorders share the selective loss of retinal ganglion cells [14]. Common genetic variants in OPA1, including rs166850 and rs10451941, have been associated with normal tension glaucoma [15,16], a disorder which also shares the selective loss of retinal ganglion cells with LHON and DOA [16]. OPA1 expression also appears to be downregulated in LHON patients [17].

With this in mind, we tested the following two hypotheses in three independent cohorts. (1) Cosegregating pathogenic mutations in OPA1 might explain why only approximately 40% of men harboring pathogenic LHON mtDNA mutations develop visual failure. This was achieved by sequencing the entire coding region of OPA1 in pairs of clinically discordant male siblings. (2) Two functional OPA1 SNPs, rs166850 and rs10451941, which were previously implicated in the pathogenesis of optic neuropathy [16], might modulate the phenotype in LHON pedigrees. This was achieved by carrying out: (a) a family-based association study of a large, well-characterized LHON pedigree, and (b) a population-based association study of LHON mutation carriers from across Europe. Given the established role of mtDNA haplogroups in modulating the clinical presentation of specific LHON mutations [18], our analysis incorporated previously determined haplogroup data.

Methods

Subjects

Hypothesis 1 was tested in 16 discordant sib pairs. Hypothesis 2 was tested in a large Brazilian m.11778G>A LHON pedigree [19] (study group 2; clinically affected, n=23; clinically unaffected, n=39) as well as in an independent cohort of 248 LHON mtDNA mutation carriers (study group 3: clinically affected, n=95; clinically unaffected, n=153) from centers around Europe. The clinical phenotype was determined by a local ophthalmologist, and all subjects were homoplasmic for one of the three primary LHON mtDNA mutations (study group 1 - clinically affected mt.11778G>A=16 and clinically unaffected mt.11778G>A=16; study group 2 - clinically affected mt.11778G>A=23 and clinically unaffected mt.11778G>A=39; study group 3 - clinically affected, mt.3460G>A=12, mt.11778G>A=81, mt.14484T>C=2 and clinically unaffected, mt.3460G>A=26, mt.11778G>A=126, mt.14484 T>C=1). This was confirmed by direct sequencing of the relevant mitochondrial NADH dehydrogenase genes (MTND-1, −4 and −6) or by PCR-restriction fragment-length polymorphism analysis, as previously described [20]. Unaffected carriers were classified and included only if they had remained asymptomatic until over 30 years of age.

Molecular studies

Study group 1

Direct sequencing of OPA1 coding regions was performed using sequencing methodologies (Applied Biosystems, Foster City, CA). Sequence chromatograms were directly compared with the appropriate GenBank reference sequence (NM_015560.1) using SeqScape software (v2.1, Applied Biosystems). Splice-site prediction was performed using GeneSplicer [21].

Study group 2

Genotyping for rs166850 and rs10451941 was performed by restriction fragment-length polymorphism analysis with specific primers for both genotypes (sense, 5′-CCC TTT TAG TTT TTA CGA TGA AGA-3′; antisense, 5′-TTG CTT AAG ACA TTA CTT GGA ACA-3′). The restriction enzymes RsaI and FspBI (Fermentas, York, UK) discriminated the respective genotypes.

Study group 3

Genotyping for rs166850 and rs10451941 was performed by primer extension of allele-specific extension products by matrix-associated laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF; Seqeunom, San Diego, CA). Genotypes were confirmed in 10% of random samples, by direct sequencing using a genetic analyzer (ABI3100; Applied Biosystems).

Statistical analysis

Allele and genotype frequencies were compared using Pearson’s chi-square test. Multiple logistic regression was performed to look for interactions between the variables. All analyses were performed using the Statistical Package for Social Sciences software (version 17.0; SPSS Inc., Middlesex, UK).

Results

OPA1 sequencing in study group 1

Sequencing of OPA1 coding regions in LHON sib pairs did not identify any previously reported pathogenic mutations in LHON sib pairs [22]. Seven previously reported synonymous polymorphisms were identified (rs7624750, rs60201300, rs34307082, rs10451941, rs9831900, rs9851685, and rs10937595) [23]; however, none segregated with the disease either individually (Table 1) or in different combinations, and no variant was predicted to disrupt exon splicing. The frequency of these variants was not significantly different from that of the background population.

Table 1
Allelic frequency comparison of SNPs identified in study group 1, discordant LHON sib-pairs (where A=affected, U=unaffected sibling and P is uncorrected probability by Fishers Exact test).

rs166850 and rs10451941 genotyping

Study group 2

There was no association between either rs166850 or rs10451941 and visual failure in the large Brazilian m.11778G>A pedigree for both alleles, independently (Pearson’s p=0.669 and p=1.00, respectively; Table 2) or for the genotypes (Pearson’s p=0.491 and p=0.966, respectively; Table 2).

Table 2
Analysis of OPA1: rs166850 and rs10451941 frequencies in study group 2, the Brazilian LHON pedigree (where, A=affected; U=unaffected, and P in uncorrected probability by Pearson’s chi-square test).

Study group 3

There was no association between rs166850 or rs10451941 and visual failure in the European LHON mutation carriers when comparing alleles (Pearson’s p=0.115 and p=1.00, respectively; Table 3) or genotypes (Pearson’s p=0.161 and p=0.959, respectively; Table 3). As previous studies have shown, the rs166850: rs10451941 CT:TT genotype is associated with increased risk of developing normal tension glaucoma (NTG), which, comparable to LHON, preferentially affects the retinal ganglion cell [16]. We therefore performed analyses of rs166850: rs10451941 complex genotypes versus LHON (Table 4). Tests of association did not reveal any link between any complex genotype and visual loss in subjects harboring a pathogenic LHON mutation.

Table 3
Analysis of OPA1: rs166850 and rs10451941 frequencies in study group 3, European LHON mutation carriers (where, A=affected; U=unaffected, and P in uncorrected probability by Pearson’s chi-square test).
Table 4
Further analysis of OPA1 rs166850:rs10451941complex genotype frequencies in study group 3, European LHON mutation carriers (where, A=affected; U=unaffected and P is uncorrected probability by Fishers Exact test).

Relationship to mitochondrial DNA haplogroup J

The clinical penetrance of the LHON mutations m.11778G>A and m.14484T>C is strongly associated with mitochondrial haplogroup J [18]. With this is mind, we compared OPA1 rs166850 and rs10451941 genotypes in both LHON J and non-J haplogroups by logistic regression analysis, which controls for age, gender, and the specific LHON mtDNA mutation. This failed to identify an interacting association between the background mitochondrial haplogroup J, the OPA1 rs166850 and rs10451941 genotypes, and the incidence of visual failure in LHON patients (p values: rs166850 genotype, p=0.464; for rs10451941 genotype, p=0.801; for combined complex genotypes, p=0.616). There was also no significant association identified in non-J haplogroups.

Discussion

This study was designed to test the hypothesis that genetic variation in OPA1 is the major factor determining why only the minority of LHON mtDNA mutation carriers develop visual failure. Our study of three independent cohorts found no evidence to support this hypothesis. Whole-gene sequencing in discordant sib pairs did not identify a pathogenic OPA1 variant. The polymorphic variants that were identified were synonymous and poorly conserved in the population (mean population heterozygosity; rs35801538=0.031, rs9851685=0.495, and rs35540805=0.027, dbSNP, [23]), and not previously associated with visual failure. Unlike glaucoma, we were unable to identify an association between the rs166850: rs10451941 genotype and the risk of visual impairment in a large, well characterized Brazilian LHON pedigree (study group 2). Being maternally related, all of the Brazilian mutation carriers harbored the same LHON mtDNA mutation (m.11778G>A) and belonged to the same mtDNA background haplogroup (J) [19]. Given the well established relationship between visual loss and both the specific mtDNA mutation and the background mtDNA haplogroup [18], we studied a third group and determined the relationship between the clinical phenotype and both rs166850 and rs10451941 in isolation; a multivariate analysis accounted for the specific primary mtDNA LHON mutation and the mtDNA haplogroup (study group 3). Once again we found no evidence of an association between common functional genetic variants of OPA1 and visual failure in LHON mtDNA mutation carriers.

Having tested the hypothesis in several different ways and in different cohorts, we conclude that it is unlikely that genetic variation in OPA1 makes a major contribution to the risk of blindness in LHON mutation carriers. Although we cannot exclude a more subtle genetic effect, such as an influence on the age at onset of the visual failure or chance of recovery, either directly or through an interaction with other genes, a much larger study is required to address this issue. This may not be technically possible, given the relative rarity of LHON mtDNA mutation carriers in the general population. Based on the results presented here, it seems more likely that other genetic and environmental factors explain the variable penetrance of this mtDNA disorder [24].

Acknowledgments

PFC is a Wellcome Trust Senior Fellow in Clinical Science and a UK NIHR Senior Investigator who also receives funding from the Medical Research Council (UK), the UK Parkinson Disease Society, and the UK NIHR Biomedical Research Centre for Aging and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust; this study has also been supported by a Telethon-Italy grant to V.C. (grant #GGP06233).

References

1. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004;23:53–89. [PubMed]
2. Brown MD, Allen JC, Van Stavern GP, Newman NJ, Wallace DC. Clinical, genetic, and biochemical characterization of a Leber hereditary optic neuropathy family containing both the 11778 and 14484 primary mutations. Am J Med Genet. 2001;104:331–8. [PubMed]
3. Bu XD, Rotter JI. X chromosome-linked and mitochondrial gene control of Leber hereditary optic neuropathy: Evidence from segregation analysis for dependence on X chromosome inactivation. Proc Natl Acad Sci USA. 1991;88:8198–202. [PubMed]
4. Chen JD, Denton MJ. X-chromosomal gene in Leber hereditary optic neuroretinopathy. Am J Hum Genet. 1991;49:692–3. [PubMed]
5. Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. Am J Hum Genet. 1995;57:77–86. [PubMed]
6. Hudson G, Keers S, Yu Wai Man P, Griffiths P, Huoponen K, Savontaus ML, Nikoskelainen E, Zeviani M, Carrara F, Horvath R, Karcagi V, Spruijt L, de Coo IF, Smeets HJ, Chinnery PF. Identification of an X-chromosomal locus and haplotype modulating the phenotype of a mitochondrial DNA disorder. Am J Hum Genet. 2005;77:1086–91. [PubMed]
7. Phasukkijwatana N, Kunhapan B, Stankovich J, Chuenkongkaew WL, Thomson R, Thornton T, Bahlo M, Mushiroda T, Nakamura Y, Mahasirimongkol S, Tun AW, Srisawat C, Limwongse C, Peerapittayamongkol C, Sura T, Suthammarak W, Lertrit P. Genome-wide linkage scan and association study of PARL to the expression of LHON families in Thailand. Hum Genet. 2010;128:39–49. [PubMed]
8. Lodi R, Tonon C, Valentino ML, Iotti S, Clementi V, Malucelli E, Barboni P, Longanesi L, Schimpf S, Wissinger B, Baruzzi A, Barbiroli B, Carelli V. Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy. Ann Neurol. 2004;56:719–23. [PubMed]
9. Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko GV, Rudka T, Bartoli D, Polishuck RS, Danial NN, De Strooper B, Scorrano L. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell. 2006;126:177–89. [PubMed]
10. Olichon A, Landes T, Arnaune-Pelloquin L, Emorine LJ, Mils V, Guichet A, Delettre C, Hamel C, Amati-Bonneau P, Bonneau D, Reynier P, Lenaers G, Belenguer P. Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis. J Cell Physiol. 2007;211:423–30. [PubMed]
11. Brown J, Jr, Fingert JH, Taylor CM, Lake M, Sheffield VC, Stone EM. Clinical and genetic analysis of a family affected with dominant optic atrophy (OPA1). Arch Ophthalmol. 1997;115:95–9. [PubMed]
12. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, Astarie-Dequeker C, Lasquellec L, Arnaud B, Ducommun B, Kaplan J, Hamel CP. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000;26:207–10. [PubMed]
13. Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, Rodriguez M, Kellner U, Leo-Kottler B, Auburger G, Bhattacharya SS, Wissinger B. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26:211–5. [PubMed]
14. Carelli V, La Morgia C, Valentino ML, Barboni P, Ross-Cisneros FN, Sadun AA. Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders. Biochim Biophys Acta. 2009;1787:518–28. [PubMed]
15. Aung T, Ocaka L, Ebenezer ND, Morris AG, Brice G, Child AH, Hitchings RA, Lehmann OJ, Bhattacharya SS. Investigating the association between OPA1 polymorphisms and glaucoma: comparison between normal tension and high tension primary open angle glaucoma. Hum Genet. 2002;110:513–4. [PubMed]
16. Yu-Wai-Man P, Stewart JD, Hudson G, Andrews RM, Griffiths PG, Birch MK, Chinnery PF. OPA1 increases the risk of normal but not high tension glaucoma. J Med Genet. 2010;47:120–5. [PubMed]
17. Abu-Amero KK, Jaber M, Hellani A, Bosley TM. Genome-wide expression profile of LHON patients with the 11778 mutation. Br J Ophthalmol. 2010;94:256–9. [PubMed]
18. Hudson G, Carelli V, Spruijt L, Gerards M, Mowbray C, Achilli A, Pyle A, Elson J, Howell N, La Morgia C, Valentino ML, Huoponen K, Savontaus ML, Nikoskelainen E, Sadun AA, Salomao SR, Belfort R, Jr, Griffiths P, Man PY, de Coo RF, Horvath R, Zeviani M, Smeets HJ, Torroni A, Chinnery PF. Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am J Hum Genet. 2007;81:228–33. [PubMed]
19. Shankar SP, Fingert JH, Carelli V, Valentino ML, King TM, Daiger SP, Salomao SR, Berezovsky A, Belfort R, Jr, Braun TA, Sheffield VC, Sadun AA, Stone EM. Evidence for a novel x–linked modifier locus for leber hereditary optic neuropathy. Ophthalmic Genet. 2008;29:17–24. [PubMed]
20. Taylor RW, Taylor GA, Durham SE, Turnbull DM. The determination of complete human mitochondrial DNA sequences in single cells: implications for the study of somatic mitochondrial DNA point mutations. Nucleic Acids Res. 2001;29:E74–4. [PMC free article] [PubMed]
21. Pertea M, Lin X, Salzberg SL. GeneSplicer: a new computational method for splice site prediction. Nucleic Acids Res. 2001;29:1185–90. [PMC free article] [PubMed]
22. Ferré M, Amati-Bonneau P, Tourmen Y, Malthiery Y, Reynier P. eOPA1: an online database for OPA1 mutations. Hum Mutat. 2005;25:423–8. [PubMed]
23. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308–11. [PMC free article] [PubMed]
24. Kirkman MA, Yu-Wai-Man P, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, Chinnery PF. Gene-environment interactions in Leber hereditary optic neuropathy. Brain. 2009;132:2317–26. [PMC free article] [PubMed]

Articles from Molecular Vision are provided here courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China